<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(5)</volume><submitter>Thilly N</submitter><pubmed_abstract>&lt;h4>Importance&lt;/h4>The human papillomavirus (HPV) vaccine is safe and effective, yet vaccination coverage remains below public health objectives in many countries.&lt;h4>Objective&lt;/h4>To examine the effectiveness of a 3-component intervention on HPV vaccination coverage among adolescents aged 11 to 14 years 2 months after the intervention ended, each component being applied alone or in combination.&lt;h4>Design, setting, and participants&lt;/h4>A cluster randomized trial with incomplete factorial design (PrevHPV) was conducted between July 1, 2021, and April 30, 2022, in French municipalities receiving 0, 1, 2, or 3 components of the intervention. Randomization was stratified by school district and municipalities' socioeconomic level. Analyses were carried out on 11- to 14-year-old adolescents livi</pubmed_abstract><journal>JAMA network open</journal><pagination>e2411938</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11117086</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effectiveness of a School- and Primary Care-Based HPV Vaccination Intervention: The PrevHPV Cluster Randomized Trial.</pubmed_title><pmcid>PMC11117086</pmcid><pubmed_authors>Adam I</pubmed_authors><pubmed_authors>Hagiu DP</pubmed_authors><pubmed_authors>Simon M</pubmed_authors><pubmed_authors>Bonnay S</pubmed_authors><pubmed_authors>Zuo M</pubmed_authors><pubmed_authors>Barret AS</pubmed_authors><pubmed_authors>Thilly N</pubmed_authors><pubmed_authors>Ecollan M</pubmed_authors><pubmed_authors>Tron A</pubmed_authors><pubmed_authors>Lasset C</pubmed_authors><pubmed_authors>Simony M</pubmed_authors><pubmed_authors>Branchereau M</pubmed_authors><pubmed_authors>Bocquier A</pubmed_authors><pubmed_authors>Raude J</pubmed_authors><pubmed_authors>Le Bel J</pubmed_authors><pubmed_authors>Bruel S</pubmed_authors><pubmed_authors>Agrinier N</pubmed_authors><pubmed_authors>Botelho-Nevers E</pubmed_authors><pubmed_authors>Jambon G</pubmed_authors><pubmed_authors>Darlington E</pubmed_authors><pubmed_authors>Gagneux-Brunon A</pubmed_authors><pubmed_authors>Pinot J</pubmed_authors><pubmed_authors>Gauchet A</pubmed_authors><pubmed_authors>Marie Dit Asse L</pubmed_authors><pubmed_authors>Michel M</pubmed_authors><pubmed_authors>Mueller JE</pubmed_authors><pubmed_authors>Levy-Bruhl D</pubmed_authors><pubmed_authors>Le Duc-Banaszuk AS</pubmed_authors><pubmed_authors>Chyderiotis S</pubmed_authors><pubmed_authors>Partouche H</pubmed_authors><pubmed_authors>Oudin-Doglioni D</pubmed_authors><pubmed_authors>Giraudeau B</pubmed_authors><pubmed_authors>Bonmarin I</pubmed_authors><pubmed_authors>PrevHPV Study Group</pubmed_authors><pubmed_authors>Epaulard O</pubmed_authors><pubmed_authors>Rossignol L</pubmed_authors><pubmed_authors>Kalecinski J</pubmed_authors><pubmed_authors>Sicsic J</pubmed_authors><pubmed_authors>Nekaa M</pubmed_authors><pubmed_authors>Vareilles G</pubmed_authors><pubmed_authors>Ailloud J</pubmed_authors><pubmed_authors>Chevreul K</pubmed_authors><pubmed_authors>Gilberg S</pubmed_authors><pubmed_authors>Bros J</pubmed_authors><pubmed_authors>Castagnet C</pubmed_authors><pubmed_authors>Dussault J</pubmed_authors><pubmed_authors>Pulcini C</pubmed_authors><pubmed_authors>Jeanleboeuf F</pubmed_authors><pubmed_authors>Juneau C</pubmed_authors><pubmed_authors>Fall E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effectiveness of a School- and Primary Care-Based HPV Vaccination Intervention: The PrevHPV Cluster Randomized Trial.</name><description>&lt;h4>Importance&lt;/h4>The human papillomavirus (HPV) vaccine is safe and effective, yet vaccination coverage remains below public health objectives in many countries.&lt;h4>Objective&lt;/h4>To examine the effectiveness of a 3-component intervention on HPV vaccination coverage among adolescents aged 11 to 14 years 2 months after the intervention ended, each component being applied alone or in combination.&lt;h4>Design, setting, and participants&lt;/h4>A cluster randomized trial with incomplete factorial design (PrevHPV) was conducted between July 1, 2021, and April 30, 2022, in French municipalities receiving 0, 1, 2, or 3 components of the intervention. Randomization was stratified by school district and municipalities' socioeconomic level. Analyses were carried out on 11- to 14-year-old adolescents livi</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-03T03:58:19.742Z</modification><creation>2026-04-24T03:09:51.185Z</creation></dates><accession>S-EPMC11117086</accession><cross_references><pubmed>38780943</pubmed><doi>10.1001/jamanetworkopen.2024.11938</doi></cross_references></HashMap>